Nestle accelerated a push into the fast-growing skincare market on Wednesday, buying the rights to several injectable treatments for facial wrinkles and lines from Valeant International for $1.4 billion. This new venture follows the acquisition by Nestle this February of Galderma dermatology from L’Oreal.
Nestle said the deal with Valeant would give it the U.S. and Canadian rights to sell the Restylane, Perlane and Emervel injectable cosmetic treatments it already manufactures, as well as Dysport, a cosmetic treatment owned by Ipsen. It is also acquiring from Valeant a skin filler for cosmetic and medical use called Sculptra.
For Nestle, the deal marks the latest step in its quest started almost two decades ago by Chairman and then-CEO Peter Brabeck-Lemathe to transform the food company into a global leader in nutrition, health and wellness, although some analysts question whether cosmetic skin treatments fit into that category.
More from NEWS
Bernard Arnault is betting on family unity to guarantee the long-term future of LVMH
Bernard Arnault is betting on family unity to guarantee the long-term future of his luxury empire. At LVMH Moët Hennessy …
Hugo Boss launches new denim line Hugo Blue
Hugo Boss has unveiled a first look at its new denim line Hugo Blue. The line from the younger Hugo …
Brunello Cucinelli sales in the first quarter of 2024 increased 16.5 percent
Despite the macroeconomic and social uncertainties and a general slowdown in the luxury fashion segment, Italian luxury house of Brunello …